tbuckley/cabot-search huggingface dataset:
Protection of Cats Against Progressive Fibrosarcomas and Persistent Leukemia Virus Infection by Vaccination With Feline Leukemia Cells&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: C K Grant, F de Noronha, C Tusch, M T Michalek, M F McLane
Journal: JNCI Journal of the National Cancer Institute (1980)

Young cats (3-6 mo old) were challenged with oncogenic Snyder-Theilen feline sarcoma virus (FeSV) after vaccination with live or killed FL74 cat lymphoma cells. Compared with controls immunized with normal cat fibroblasts, the FL74-vaccinated cats exhibited increased resistance to FeSV-induced progressive primary and disseminated secondary tumors. Maximum protection was achieved by vaccination with live FL74 cells or with a low dose of freeze-thawed cells, but tumor cells inactivated by glutaraldehyde or paraformaldehyde were also effective. Infectious helper feline leukemia virus (FeLV) was detected in the blood of all cats after FeSV challenge, but the duration and magnitude of this viremia were reduced in animals that had been previously vaccinated with live, freeze-thawed, or paraformaldehyde-fixed cells. Although immunized cats were resistant to FeSV-induced tumors and FeLV viremia, no evidence was obtained to suggest that vaccination with dead cells induced detectable circulating antibody prior to challenge with oncogenic virus. After FeSV challenge, complement-dependent antibody to feline oncornavirus-associated cell membrane antigen (CDA-FOCMA) appeared at high titer in cats that were destined either to survive tumor-free or to develop small, localized, and eventually regressing tumors. Cats immunized with live FL74 cells developed CDA-FOCMA prior to challenge, and antibody appeared in these cats following an episode of transient FeLV viremia induced by virus replicating from the injected tumor cells. Therefore, apparently, a state of transient or persistent FeLV viremia regularly preceded detection of CDA-FOCMA activity. Several individually derived feline lymphoma cell lines were used as targets for CDA-FOCMA, and the results suggested that lytic activity is directed to multiple antigen determinants expressed differently by individual feline lymphomas.
Excess lifetime costs associated with colorectal cancer among elderly Medicare beneficiaries: Evidence from SEER-Medicare data
Authors: K. Lang, L. M. Lines, D. W. Lee, J. R. Korn, D. J. Vanness, C. C. Earle, J. Menzin
Journal: Journal of Clinical Oncology (2008)

4044 Background: Data on lifetime colorectal cancer (CRC) treatment costs by stage and age at detection are limited and outdated. This study provides more current and detailed estimates of CRC treatment costs. Methods: This retrospective cohort study includes patients aged ≥ 65 years newly diagnosed with CRC in a SEER registry between 1996 and 2002 (n=60,916) and 1:1 matched (by age, sex, and geographic region) non-cancer comparison patients from a 5% sample of Medicare beneficiaries. The Kaplan-Meier Sample Average estimator was used to estimate observed 10-year costs, which we then extrapolated to 25 years using standard techniques. Costs represent all provider payments and were stratified by stage and age at diagnosis. A secondary analysis computed costs on a per- survival-year basis to adjust for differences in mortality by stage and age. Excess costs were costs in excess of those for matched comparison patients. Costs were expressed in 2006 US$, with future costs discounted 3% per year. Results: Lifetime total excess CRC costs were $28,987, with an inverted U-shaped pattern by stage ($40,069, $45,816, $43,382, $42,362 and -$10,471 in Stages 0–4, respectively), and a U-shaped pattern by age (65–74: $37,501; 75–84: $20,087; 85+: $24,192). On a per-survival-year basis, excess CRC costs were approximately 9 times greater for patients diagnosed at Stage 4 vs. Stage 0 ($3,390, $4,271, $6,587, $10,358 and $30,120 in Stages 0–4, respectively) and also increased by age at diagnosis (65–74: $8,609; 75–84: $9,267; 85+: $12,564). Conclusions: Excess costs associated with colorectal cancer are substantial and increase considerably by stage and age at diagnosis on a per-survival-year basis. Interventions aimed at earlier diagnosis and prevention have the potential for sizable economic benefits. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GE Healthcare GE Healthcare
The economic implications of rasburicase treatment in adult tumor lysis syndrome patients
Authors: M. Eaddy, K. O’Day, K. M. Tangirala, B. Seal
Journal: Journal of Clinical Oncology (2009)

e17503 Background: Rasburicase is a recombinant urate-oxidase enzyme used to reduce high levels of plasma uric acid (UA) resulting from tumor lysis syndrome (TLS). Rasburicase reduces UA levels within 4 hours of administration, minimizing risk of serious complications from TLS. Treatment pattern analyses indicate rasburicase is often used in combination with allopurinol; however, no studies have evaluated clinical and economic consequences of this pattern of care. The purpose of the study was to compare hospitalization costs, length of stay (LOS), and duration of critical care in patients receiving rasburicase with or without allopurinol. Methods: Patients in the Premier hospital database administered rasburicase or combination therapy within 2 days of hospital admission were eligible for study inclusion. Patients were excluded if they were &lt;18 years of age or received hemodialysis on admission. Patients were propensity score matched to rasburicase patients based on gender, race, hospital type, provider type, payer type, admission source, use of electrolyte modification therapy, critical care admission, and comorbid diagnoses. Differences in health care costs, LOS, and duration of subsequent critical care were assessed using exponentially distributed generalized linear models with a log link function. Projection weights are used to produce national projected patient counts. Results: There were 280 rasburicase and 310 combination patients matched in the analysis. Mean age of the sample was 65.2, with 31% being female. There were no statistical differences in matched covariates across the cohorts. Rasburicase patients incurred an average total cost of $39,474 per hospitalization compared to $52,047 for combination patients (p = 0.0029). Rasburicase patients also had a lower LOS (10.5 days) compared to combination therapy (16.4 days, p &lt; 0.0001). Duration of critical care was similar in both cohorts (rasburicase = 1.4 days vs 1.8 days, p = 0.1222). Conclusions: Combination therapy of rasburicase and allopurinol resulted in higher total hospitalization costs and longer LOS compared to rasburicase monotherapy. [Table: see text]
Girl should have been offered a chance of safety
Authors: J. Butler
Journal: BMJ (1996)

EDITOR,—I read the recent ethical debate on child protection with increasing uneasiness.1 Although the priority of the child's welfare and the danger of professionals “going it alone” are pointed out, other important issues are not addressed.

Did it not seem worrying to the general practitioner that the girl behaved as she did when the allegations were made? Phrases such as “she offered no explanation” indicate to …
Nutritional attitudes of recently diagnosed cancer patients
Authors: J. M. Metz, K. Claghorn, E. Sweeney-Cordis, M. Hampshire
Journal: Journal of Clinical Oncology (2005)

8011 Introduction: While maintaining nutritional status is an important component of cancer care, data on attitudes of cancer patients regarding nutrition and nutritional interventions during treatment are limited. This questionnaire was designed to evaluate cancer patient attitudes and concerns regarding nutrition during cancer therapy. Materials and Methods: Between 9/04–11/04, a piloted questionnaire assessing demographics and nutritional attitudes during cancer treatment was completed by 200 recently diagnosed cancer patients on the OncoLink website (www.oncolink.org). Most patients were Caucasian (85%), female (75%), and from the US (75%). The mean age was 53 years (mean= 51; range= 11–91 years). The most common cancer diagnoses were breast (38%), colorectal (6%), and prostate (6%). Patients were treated at an academic medical center (39%), community hospital (31%), or private physicians’ office (30%). Results: After diagnosis, 69% of patients actively sought nutritional information. The most common sources of nutritional information included the Internet (70%), books (63%), physicians’ office (53%), friends and family (31%), and health food stores (29%). A registered dietitian (RD) was available during treatment to 31% of patients. Of those who met with an RD, 88% felt their consultation an important component of their cancer care. Patients at an academic medical center were more likely to have a RD available for counseling (43% vs 26%; p=.025). Nutrition counseling was sought outside of the treating medical facility by 41% of patients; most common providers were naturopathic practitioner (35%), RD (28%), and herbalist (9%). Patients believed that diet and nutrition influenced the response of their cancer to conventional cancer therapy (90%), while half (53%) believed their physicians felt the same way (p<.001). Conclusions: Cancer patients view nutrition as an important component of their cancer therapy. A minority met with a registered dietitian as part of their medical team, but many search for nutritional information from sources outside of the treating medical facility. Cancer care providers and treatment facilities should provide patients broader nutrition resources and access to nutrition education. No significant financial relationships to disclose.
Concurrent Chemoradiation with Three Weekly Versus Weekly Cisplatin in Locally Advanced Nasopharyngeal Cancer Patients
Authors: Ji Yun Lee, Jong-Mu Sun, Sung-Bae Kim, Keon Uk Park, Hoon-Kyo Kim, Dae Sik Hong, Jun Suk Kim, Keunchil Park, Yong Chan Ahn, Myung-Ju Ahn
Journal: Annals of Oncology (2014)
Assessment of medication safety in the outpatient setting
Authors: J. R. Hoverman, K. M. Shuey, D. Richardson, K. Hansen, P. C. Dugger
Journal: Journal of Clinical Oncology (2007)

6631 Background: US Oncology provides the pharmacy and drug infusion support for over 700 medical oncologists and hematologists. As such medication safety is a principle concern for the delivery of quality care. As described earlier, a survey of affiliated practices indicated three areas of concern: 1) no uniform reporting mechanism, 2) no standard double check mechanism, and 3) variable inclusion of medication safety procedures and reporting into practice operations. This report describes the first three years experience and proposals for continuing improvement. Methods: An online reporting tool was made available to all practices. 337 practice sites and 35 practice groups were monitored. The first hour of chemotherapy (1HC) was used as the denominator for all occurrence calculations. All reporting was voluntary. Occurrences were rated as to severity, from 1 (error detected before any steps towards completion) to 7 (error resulting in death of the patient). The occurrences were categorized according to process, either in prescribing, calculation of doses, lab or allergy issues, or matching the mixed dose to the order or in administering a mixed dose. In each circumstance a near miss or failure to double check was determined. The total experience for the network was determined for 2004 and 2005 with projected data for 2006. Results: The 1HC numbers used as denominators are: 2004–534,542: 2005–534,606: 2006 –542,000. Occurrences with error rates were: 2004 –1,723 (0.32%), 2005 –2,467 (0.46%), 2006 –2,653 (0.49%). The percent practices participating were 70%, 83% and 75% for 2004, 2005 and 2006 respectively. When considering only reporting practices the occurrence rates were: 2004 –0.45%, 2005–0.55%, 2006–0.65%. The percent occurrences with temporary or permanent harm to the patient dropped from 19% in 2004 to 16% in 2006. A failure to double check was a contributing factor in 57% in 2004, 42% in 2006. Conclusions: An anonymous reporting mechanism resulted in an increase in occurrence reporting. An education program led to fewer failures to double check and a decrease in events causing harm to patients. Next steps include enhanced feedback to practices and the use of an EHR to improve processes. The malpractice environment in some areas inhibits reporting. No significant financial relationships to disclose.
The impact of targeted molecular therapy on the level of renal cell carcinoma (RCC) venous tumor thrombus.
Authors: N. G. Cost, S. E. Delacroix, J. P. Sleeper, P. J. Smith, R. F. Youssef, B. F. Chapin, J. A. Karam, S. H. Culp, E. J. Abel, J. Brugarolas, G. Raj, A. I. Sagalowsky, C. G. Wood, V. Margulis
Journal: Journal of Clinical Oncology (2011)

e15002 Background: Targeted molecular therapies (TMTs) have demonstrated activity in RCC by reducing the size of primary tumors and metastases. Thus, we assessed the treatment effect of TMTs on IVC tumor thrombi. Methods: A multi-institutional database of patients treated with TMTs with in situ RCC was reviewed, patients with an IVC thrombus were assessed for radiographic responses in thrombus size and location. We then described the pre- and post-treatment characteristics of this group. Results: In the 25 patients meeting inclusion criteria, pre-therapy biopsy showed ccRCC in 19 and unclassified RCC in 6. Prior to TMT, the thrombus level was II in 18 (72%), III in 5 (20%), and IV in 2 (8%). The TMT was sunitinib in 12 cases and non-sunitinib in the other 13. Median duration of TMT was 2mo (1-9). Following TMT, 7 (28%) had an increase (↑) in the thrombus height above the renal vein (RV), 7 (28%) had no change and 11 (44%) had a decrease (↓). The median Δ of the thrombus height was 0cm (-8.5-5), and the median Δ of the thrombus diameter was -0.1cm (-1.6-0.9). The Δ in the tumor thrombus level classification after TMT was: 1 (4%) had an ↑, 21 (84%) were stable and 3 (12%) had a ↓. In only 1 case (4%) the surgical approach was potentially affected by regression (level IV → III). Regression resulting in a Δ in the clinical level of the thrombus was only seen in the sunitinib cohort. Yet, the Δ in thrombus height, diameter or clinical level classification between sunitinib and non-sunitinib cohorts did not reach statistical significance (Table). No significant predictors of thrombus response to TMT were found. Conclusions: TMTs had minimal clinical effect on RCC tumor thrombi. Only patients treated with sunitinib had measurable thrombus regression; however, the magnitude of this effect was not statistically significant and is of unclear clinical relevance. Sunitinib Non-sunitinib Initial thrombus level II III IV 8 pts 2 pts 2 pts 10 pts 3 pts 0 pts 0.5 Δ in thrombus level ↑ - 0 (0%) Stable - 9 (75%) ↓ - 3 (25%) (1 – level IV → III, 1 – III → II, 1 – II → 0) ↑ - 1 (7.7%) (II → III) Stable - 12 (92.3%) ↓ - 0 (0%) 0.1 Median initial height above RV 3.9 (2 - 14.5) 3.5 (0 - 8.5) 0.2 Median Δ in height above RV 0.28 (-8.5 - 0.5) 0 (-4 to 5) 0.2 Median Δ in max diameter -0.66 (-1.5 - 0.64) 0 (-1.6 - 0.9) 0.1
Tumor control and objective responses: single-center experience with ecteinascidin-743 (ET-743), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas
Authors: P. Schöffski, G. Huygh, P. Clement, J. M. Jimeno, H. Wildiers, H. Dumez, J. Selleslach, R. Sciot, I. de Wever, A. T. van Oosterom
Journal: Journal of Clinical Oncology (2005)

9027 Background: ET-743 (Yondelis) is a marine-derived minor-groove binder which interferes with gene activation and nucleotide excision repair, modulates drug-resistance, induces DNA strand breaks, affects the microtubules and blocks the cell cycle in S and G2. The drug is active in a variety of tumors in vitro and in vivo and responses were observed in sarcoma pts in early studies. We performed a retrospective single-center analysis of treatment outcome with ET-743, mainly involving individuals treated in a named-patient compassionate use program. Written informed consent was obtained from all pts. Methods: ET-743 was administered at dosages of 900-1500 μg/m2 as a 24 h iv. infusion q3w. Treatment was continued until progression or excessive toxicity. Results: 89 patients (median age 49 yrs, performance status 0–2) were analyzed. All of them had documented progressive sarcoma at start of treatment. The most common tumor types were leiomyo- (29), lipo- (16) and osteosarcoma (14). Pts had received a median of 2 prior chemotherapy regimens (range, 0–6). Pretreatment included anthracyclins (93%), ifosfamide (74%) and other drugs. 430 cycles were evaluated (median 4.8 per pat., range 1–31). All pts were assessed for toxicity (NCI CTC 2.0), and the most relevant side effects were neutropenia, thrombopenia, anemia, transaminitis, anorexia, asthenia and nausea/vomiting. The most common reasons for dose reductions were thrombopenia, neutropenia, transaminitis and infections. 70% of the patients discontinued ET-743 due to progression. 82 patients were evaluable for response (RECIST): CR 1, PR 5, MR 1, SD (> 6 mo.) 16, SD (2–6 mo.) 16 and PD 43. The objective response rate (CR+PR) was 6.7% and the clinical benefit rate (CR+PR+MR+SD) at 3 and 6 mo. was 41.6 and 23.4%. Responses included pts with lipo-, leiomyo-, osteo- and myogenic sarcoma (lung, liver and abdominal sites). The median duration of response was 9.8 mo (range 2–43). Conclusions: ET-743 induces long-lasting responses and tumor control in a clinically relevant proportion of pretreated progressive sarcoma pts. Further studies in this indication are warranted. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration PharmaMar PharmaMar
Abstract 12099: Impact of Empiric Nesiritide or Milrinone Infusion on Early Postoperative Recovery Following Fontan Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Authors: John M Costello, Carolyn Dunbar Masterson, Catherine K Allan, Kimberlee Gauvreau, Jane W Newburger, Francis X McGowan, David L Wessel, John E Mayer, Joshua W Salvin, Roger E Dionne, Peter C Laussen
Journal: Circulation (2013)

Introduction: Nesiritide has vasodilatory, lusitropic and natriuretic properties and may decrease myocardial ischemia-reperfusion injury. Milrinone is an inodilator with lusitropic effects. Althoug...
Serosurveys for West Nile Virus Infection--New York and Connecticut Counties, 2000
Journal: JAMA (2001)

In 2000 21 persons with acute illness attributed to West Nile virus (WNV) infection were reported in several counties in New York.  Because ill persons represent only a fraction of the persons who are infected many more persons probably were infected in 2000.  To determine the prevalence of recently acquired WNV infection and associated risk factors for infection random household cluster serosurveys were conducted in Staten Island (New York City) portions of Fairfield County (Connecticut) and Suffolk County (New York) during October and November 2000.  All three areas had intense WNV epizootics as determined by avian mortality and mosquito surveillance systems.  This report summarizes the preliminary results of this survey and indicates that in areas with intense epizootic WNV activity asymptomatic or mildly symptomatic human infections can occur.
Vasectomy matters. (Letter)
Authors: Schmidt Ss
Journal: JAMA (1973)

Bacterial epididymitis is rare following elective vasectomy or vasectomy due to prostatitis or cystitis or following prostatic surgery when spontaneous reanastomosis is prevented.  2 relatively common complications of vasectomy may be confused with epididymitis.  Congestive epididymitis may occur up to 6 months postoperatively.  The epididymis is tender and diffusely swollen but the discomfort abates within a week after treatment.  The second condition spermatic granuloma of the epididymis may occur several years postoperatively.  Following vasectomy the tubules dilate due to internal pressure and may rupture causing a granuloma.  Epididymectomy may be necessary.  A vasocutaneous fistula may result particularly when nonabsorbable ligatures are used.  This is a type of spermatic granuloma of the vas.
PSYCHOLOGIC FACTORS IN CHRONIC ALCOHOLISM
Authors: R S WALLERSTEIN
Journal: Annals of Internal Medicine (1958)

Article1 January 1958PSYCHOLOGIC FACTORS IN CHRONIC ALCOHOLISMROBERT S. WALLERSTEIN, M.D., F.A.C.P.ROBERT S. WALLERSTEIN, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-48-1-114 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSTATEMENT OF PROBLEMThe decision of The American College of Physicians to hold this symposium on the problem of alcoholism, and to bring the combined viewpoints of internist, sociologist and psychiatrist to bear on it, reflects our modern medical recognition of chronic alcoholism as a disease of major medical importance. This in itself marks a significant step in our understanding of this disorder, for it signifies the surmounting of the moral frame of reference within which chronic alcoholism has so long been regarded as a manifestation of ignorance, of vice, of sinfulness, or of all of these combined.In advancing... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Topeka, Kansas*From the Symposium on Alcoholism: A Complex Medical Problem, presented at the Thirty-eighth Annual Session of The American College of Physicians, Boston, Massachusetts, April 8, 1957.This paper is based on the condensation of the summary chapter of a book, Hospital Treatment of Alcoholism, by Robert S. Wallerstein, M.D., and associates, published June, 1957, by Basic Books, New York, N. Y.Requests for reprints should be addressed to Robert S. Wallerstein, M.D., Associate Director of Research, Menninger Foundation, Topeka, Kansas. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Use of DisulfiramComparison of the Importance of Alcoholics Anonymous and Outpatient Counseling to Maintenance of Sobriety among Alcohol AbusersMatching Problem Drinkers With Optimal TreatmentsThe pharmacological treatment of the addictive disordersTHE PHARMACOLOGICAL TREATMENT OF THE ADDICTIVE DISORDERSTechniques for the Use of Hypnosis in Group TherapyGroup Hypnotherapy: A Brief SurveyResearch activities related to treatment of alcoholismGroup hypnotherapy techniques with drug addicts 1 January 1958Volume 48, Issue 1Page: 114-122KeywordsAlcoholicsAlcoholismAlcohols ePublished: 1 December 2008 Issue Published: 1 January 1958 PDF downloadLoading ...